Vectormune FP ILT
Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)
Table of contents
Overview
Vectormune FP ILT is a veterinary vaccine used in chickens to reduce skin lesions due to fowlpox (FP) and to reduce the clinical signs and tracheal (windpipe) lesions due to avian infectious laryngotracheitis (ILT).
Vectormune FP ILT contains the active substance live fowlpox virus which has been modified to produce two specific proteins from the avian infectious laryngotracheitis virus.
Authorisation details
Product details | |
---|---|
Name |
Vectormune FP ILT
|
Agency product number |
EMEA/V/C/005482
|
Active substance |
recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live
|
International non-proprietary name (INN) or common name |
Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)
|
Species |
Chicken
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA-Phylaxia Co. Ltd.
|
Date of issue of marketing authorisation valid throughout the European Union |
09/12/2020
|
Contact address |
Szállás u. 5. |
Product information
Vectormune FP ILT - EMEA/V/C/005482 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.